Versant Venture Management LLC Invests $123.76 Million in LENZ Therapeutics, Inc. $LENZ

Versant Venture Management LLC purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,656,888 shares of the company’s stock, valued at approximately $123,758,000. LENZ Therapeutics comprises 58.3% of Versant Venture Management LLC’s investment portfolio, making the stock its largest position. Versant Venture Management LLC owned about 0.08% of LENZ Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. AlphaQuest LLC raised its position in shares of LENZ Therapeutics by 56.2% in the 2nd quarter. AlphaQuest LLC now owns 10,219 shares of the company’s stock valued at $300,000 after purchasing an additional 3,675 shares in the last quarter. Lisanti Capital Growth LLC grew its position in shares of LENZ Therapeutics by 41.0% during the second quarter. Lisanti Capital Growth LLC now owns 36,185 shares of the company’s stock worth $1,061,000 after buying an additional 10,520 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of LENZ Therapeutics by 15.5% in the second quarter. Geode Capital Management LLC now owns 416,122 shares of the company’s stock worth $12,198,000 after buying an additional 55,730 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in LENZ Therapeutics by 63.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 4,130 shares of the company’s stock valued at $121,000 after acquiring an additional 1,605 shares in the last quarter. Finally, Calamos Advisors LLC acquired a new stake in LENZ Therapeutics in the second quarter valued at $515,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Stock Performance

NASDAQ LENZ opened at $11.89 on Tuesday. LENZ Therapeutics, Inc. has a one year low of $11.48 and a one year high of $50.40. The company has a 50-day simple moving average of $16.16 and a 200-day simple moving average of $28.45. The firm has a market capitalization of $372.04 million, a PE ratio of -5.64 and a beta of 0.50.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on LENZ shares. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Zacks Research cut shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen cut LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.